

Signatory Name: Ferring Pharmaceuticals Pty Ltd

The question numbers in this report refer to the numbers in the report template. Not all questions are displayed in this report.

Status: Complete

Yes

1

0

The content in this APC Annual Report is hereby endorsed by the Chief Executive Officer, or equivalent officer of the organisation.

5.	i. Industry sector (please select 1 only):					
	(Brand Owner / Wholesaler / Retailer				
	0	Packaging Manufacturer				
	0	Waste Management				
	0	Other - Commercial Organisation				
	0	Community Group				

- Government
- Raw Material Supplier

Industry Association

- Other:
- 6. Industry type (please select 1 only):
 - Food & Beverage
 - Pharmaceutical / Personal Care / Medical
 - Hardware
 - Homewares
 - Communications / Electronics
 - Clothing / Footwear / Fashion
 - Chemicals / Agriculture
 - Fuel
 - Large Retailer
 - Tobacco
 - Shipping Company
 - Airline
 - Other:
- 7. Please indicate your organisation's reporting period:
 - Financial Year: 1 July 2014 30 June 2015
 - Calendar Year: 1 January 2015 31 December 2015
- 8. Was your action plan extended or updated to cover the APC transitional year (01/07/2015 -30/06/2016)?
 - Yes
 - No

lf١	291	what is	the	nerind	of v	VOLIE	extended	or II	ndated	action	nlan?
• •	y СЗ,	whatis	uic	period	O1	your	CALCITACA	Oi u	puatou	action	piaii:

If yes, what is the period of your extended or updated action plan?					
Start Date:	01/07/2015				
End Date:	30/06/2016				

G	oal 1: Design		
	PI 1: % of signatories with docume PGs or equivalent.	ented policies and proced	ures for evaluating and procuring packaging using the
9.	Does your company have docun SPGs or equivalent?	nented policies and proced	dures for evaluating and procuring packaging using the
	Yes	•	No
10	. Of the types of packaging existir using the Sustainable Packaging		reporting period, what percentage had been reviewed end of the reporting period?
	82	%	
11	. Have any new types of packagir	ng been introduced during	the reporting period?
	Yes	•	No
12	I. If yes, of the new types of packa reviewed using the Sustainable F		he reporting period, what percentage have been G) by the end of the reporting
		%	
13	. Please indicate your progress th	is year towards achieving	your annual targets and milestones for KPI 1
	Target: According to your Actio out to do?	n Plan, what did you set	Actual: What did you achieve?
1.	. Establish a documented polic		To date four SPG assessments have been conducted,

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Establish a documented policy and procedure for evaluating packaging using the SPG assessment process.	To date four SPG assessments have been conducted, with the assistance of our Head Office, representing 82% of our product placed on the Australian market. We aim to formalise this assessment process by including a local SPG assessment policy, as part of a Standard Operating Procedure, which will address the three APC Performance Goals.
2.	Establish and maintain a centralised database containing all documentation and other information relating to the APC obligations including results from the SPG assessments.	To date, Ferring Pharmaceuticals has recorded all SPG assessments on our cloud based reporting software which allows staff in Australia and overseas to collate SPG assessment information in one shared file.
3.	Document and report any actual or attempted changes to packaging identified as part of reviews.	In previous years, Ferring Pharmaceuticals Australia managed to influence the global production site to amend the presentation of a major product to supply disposables separate from the drug. This resulted in a substantial reduction in wastage of disposables. As well, Ferring Pharmaceuticals released a local product, WetAlert, which was designed so the packaging can be reused as a storage container. The product components in question are recyclable and labelled with the appropriate recycling logo.

Our focus and priority in developing our packaging always centres upon the requirements of the Therapeutic Goods Administration and accompanying Act.

Since the products that we import from overseas are developed for a global market there is no opportunity for Ferring Pharmaceuticals to significantly influence the packaging specifications. We have however made our Environment, Health and Safety Department in Head Office aware of our APC responsibilities which have assisted us, where practicable, with our SPG assessments and broader APC obligations.

Goal 2: Recycling

KPI 3: % signatories applying on-site recovery systems for used packaging.

- 15. Do you have on-site recovery systems for recycling used packaging?
 - Yes at all facilities/ sites
 - Yes at some, but not all facilities/ sites
 - No
- 16. Please indicate your progress this year towards achieving your annual targets and milestones for KPI 3

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Document baseline information for office waste and recycling and report on annual progress.	Ferring Pharmaceutical continues to recycle all paper, plastics and ink cartridges arising in our small serviced facilities comprising offices and meeting rooms.
		While our recycling impact at these premises is limited, all staff are made aware of the importance and the need to make use of these facilities as part of our signatory obligations.
		As we are in a serviced office environment we are unable to document statistics specific to our office practices as all waste and recycling is managed by the property manager.
2.	Determine the onsite waste and recycling procedures of our 3rd party logistics provider, including the reuse of secondary and tertiary packaging as protective packaging for goods outwards.	Ferring Pharmaceuticals uses a third party logistics service provider to store and then deliver our imported goods to our clients in Australia.
	packaging for goods outwards.	This is done from the service provider's national Distribution Centre in NSW, which is a state-of-the-art facility specifically designed and built for the broader healthcare industry. On this site a quality management system is in place that meets the internationally recognised Good Manufacturing Practice (GMP) Standard. This includes ensuring a clean environment, which means proactive waste and recycling practices are in place that meet TGA requirements.

Ferring Pharmaceuticals imports and distributes a range of pharmaceutical products that are fully packaged when they arrive in Australia and must comply with the Therapeutic Goods Act (TGA).

Ferring Pharmaceuticals engages a third party provider, recognised for its work with some of the world's best known brands across the pharmaceuticals, biotechnology and medical equipment industries, that operates from a purpose-designed distribution facility.

In following the Good Manufacturing Practice (GMP) Standard at the main storage facility in NSW, our provider must undertake the scheduled and timely removal for recycling of any packaging taken from our products where it is fit for purpose, otherwise it will be removed as waste from the site.

For our own serviced offices, our staff are encourage to make use of the recycling facilities available for paper, plastics and cartridges as part of our APC signatory obligations.

KPI 4: Signatories implement formal policy of buying products made from recycled packaging.

18. Does your company have a formal policy of buying products made from recycled packaging?

Yes	No	
Please explain why not		

Please explain why not

Ferring's products are 100% packaged before they arrive in Australia and we have no input to the product or packaging design process as this is carried out for a global market in our head office.

As well, we employ the services of a Third Party Logistics provider, so have no need to purchase any secondary cartons within Australia.

We are aware that our global Head Office has made reference to 'green purchasing policies' and we will follow up with our Head office contact on this matter.

While we can influence the purchasing practices within our Australian office, we have had disappointing outcomes to date in using paper (a major consumable) with recycled content, so we have not considered this option further recently.

19	ls	this	nolicy	actively	used?

	•		
0	Yes	0	No

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Examine the possibility of introducing a Buy Recycled policy.	Ferring Pharmaceutical is constrained as to the progress we can make with a Buy Recycled Policy as we do not make major purchases within our immediate operations; our main overheads in our offices being rental and the servicing of our premises. There is an opportunity for Ferring Pharmaceutical to take advantage of any global efforts in this regard and on page 20 of the Ferring Group 2014 CSR Review reference is made to green purchasing policies. We are following up with our Head Office to determine the focus and extent of these policies and if they affect any of the packaging that is imported into Australia.
2.	Identify opportunities for improvements in Buy Recycled quantities.	Ferring Pharmaceutical's products are packaged at a number of facilities around the globe. Ferring has endeavoured to use recycled materials in its outer cartons and secondary packaging which can be up to 70% content where possible.

Ferring Pharmaceutical is constrained with regard to developing a Buy Recycled Policy as we do not make major purchases of packaging in Australia and our main overheads in our offices are the rental and servicing of our premises. This goes as far as our electricity being included in our rental agreement so we cannot avail of Green Power.

The pharmaceutical nature of our products also restricts the source of the packaging that can be placed against our products so in many instances this must be a new packaging rather than a recycled option.

There is an opportunity for Ferring Pharmaceutical to engage with our global operations to ensure that there is an element of recycled material in our outer and secondary packaging as part of our packaging policy. On previously reviewed products this can be up to 70% recycled materials in the outer packaging of our products.

Goal 3: Product Stewardship

KPI 6: % signatories with formal processes to work collaboratively on packaging design and / or recycling.

22	Does you	r company	have fo	rmal pro	cesses i	n place	for c	collaboratin	g with	other	companies	or	organisations	s on
	improved	packaging	designs	s and/or	recycling	which	aims	to reduce	or elir	ninate	waste?			

Yes
No

Provide details of policies and procedures (including names of policies/ procedures)

Over the last five years we have engaged with the Head Office Environment, Health and Safety Department in Switzerland around the SPGs that we have conducted to date.

As well we have a strong contractual relationship with our 3rd Party Logistics provider which has primary responsibility, on our behalf, for storing and distributing our products around the country.

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Engage with our 3rd party logistics provider in regard to APC related information, where available, about their warehouse operations, including packaging purchases, waste and recycling practices.	We use Linfox Healthcare Logistics to provide highly specialised supply chain management services for Ferring Pharmaceuticals through its purpose designed distribution facilities.
		With a formal contract in place, we hold frequent contract management meetings to review their performance and, while we do not have direct influence over their operations, we have informed Linfox of our obligations under the Australian Packaging Covenant and are awaiting information, which they are able to share, about their operations in this regard.
2.	Liaise with the global arm of our business to identify international sustainability initiatives that impact on local operations and inform them of our APC obligations.	In 2014, the Ferring Group produced its first Corporate Social Responsibility Review, which included a number of packaging and resource management initiatives.
		We will continue to engage with our Head Office Environment, Health and Safety Department to find out how global sustainability initiatives may impact on our local operations, while providing input to Ferring's global CSR program based on meeting our APC obligations.

Through regular meetings with our third party logistics provider, we engage with them over a range of operational matters including identifying where they can respond to APC requirements across their supply chain.

In its 2014 CSR review, Ferring Group Head Office identified the importance of improving the environmental footprint of the organisation's activities throughout its full supply chain, from the sourcing of materials to the manufacture, supply and distribution of its medicines. This includes consideration of water and energy use, packaging design, and waste management practices.

Through our SPG assessments and by informing our Head Office of our APC broader obligations, we are facilitating greater engagement within the Group over supply chain matters that occur on a global scale and endeavour to identify how they impact on our operations here in Australia.

KPI 7: % signatories showing other Product Stewardship outcomes.

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?		
Participate in the roll out of Ferring Pharmaceuticals' global Corporate Social Responsibility (CSR) program.		The Australian operations will benefit from other initiatives, including the integration of environmental considerations, into the global business in several ways, including: • Quality by Design and Lean Six Sigma, • green purchasing policies, • sustainable manufacturing practices, and • training and education. All Ferring affiliates are actively encouraged to engage in activities specific to their local markets or operations.		
		We need to obtain further information from our Head office to determine how best to engage in this program.		
2.	Maintain ISO 14001 certification and environmental management system across all applicable manufacturing sites.	Ferring is progressively implementing internationally recognised management systems to ensure (global) programmes are sustainable and effective.		
		ISO14001/ OHSAS18001 standards are being followed at all our international manufacturing sites with certification by accredited registrars.		
3.	Engage in other product stewardship outcomes.	IBD ASSURANCE Programme – Asia-Pacific Developed at St Vincent's Hospital in Melbourne and the National University Hospital in Singapore, the IBD ASSURANCE programme is a web-based clinical guide, reporting system and database developed to assist in cancer surveillance in patients with inflammatory bowel disease (IBD). The project is designed to reduce the risk of patients developing colorectal cancer by offering physicians an easy way of monitoring patients. The programme was launched in January 2014, and is supported by Ferring Australia, Singapore and Hong Kong.		
		In addition, Ferring Pharmaceuticals supports the following consumer health organisations through corporate membership and project funding: • Continence Foundation of Australia • Crohn's and Colitis Association • Australian Pituitary Foundation • Access Australia		

26.	Since the beginning of th	e reporting period,	has your	company h	ad any d	other out	comes re	elated to	product
	stewardship?								

Yes
No

If yes, please give examples of other product stewardship outcomes

In 2012 the Ferring Executive Board approved the adoption of a formal approach to Corporate Social Responsibility (CSR) on a global basis. In 2013 Ferring established a cross-cultural and cross-functional global taskforce to steer the progress of CSR at Ferring. It also exists to guide and support Ferring affiliates in developing their respective journeys, help define future strategies, and to report progress to our Board on a regular basis.

In Australia, Ferring Pharmaceutical is constrained in any product stewardship initiatives we can engage in related to our immediate operations due to the limited capacity we have as a serviced office supporting our overseas Head Office.

However, our company's global philosophy is to make a difference to people's health and quality of life, both today and into the future. Therefore, we do support the following consumer health organisations through corporate membership and project funding:

- · Continence Foundation of Australia
- · Crohn's and Colitis Association
- · Australian Pituitary Foundation
- · Access Australia

In addition, we continue to support the Asia-Pacific IBD ASSURANCE Programme which is a web-based clinical guide, reporting system and database developed to assist in cancer surveillance in patients with inflammatory bowel disease (IBD).

The project is designed to reduce the risk of patients developing colorectal cancer by offering physicians an easy way of monitoring patients.

27. Describe any constraints or opportunities that affected performance under this KPI

Being a relatively small operation, with limited opportunity to directly affect stewardship outcomes on our immediate operations, we have formal contractual relationship with our 3PL provider which has an environmental policy in place to improve the resource efficiency of its operations.

In response to the company's global philosophy to make a difference to people's health and quality of life, both today and into the future, here in Australia we do support a number of consumer health organisations including the Continence Foundation of Australia and the Crohn's and Colitis Association.

KPI 8: Reductions in packaging items in the litter stream.

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Add appropriate recycling and litter management information on all primary and secondary packaging.	Ferring Pharmaceuticals has, where possible, reduced the potential for consumer litter by replacing packaging inserts through the provision of consumer medicine information electronically and allowing patients to access information online or as appropriate via the community pharmacy. Prior to this year, Ferring Pharmaceuticals released a
		local product, WetAlert, which was designed so the packaging can be reused as a storage container. The product components in question are recyclable and labelled with the appropriate recycling logo.

2.	Determine the onsite litter management practices of our 3rd party logistics provider.	As a result of regular contract management and site visits, Ferring Pharmaceuticals has determined that our 3rd party logistics provider, operating from a state of the art facility, ensures that proper OH&S requirements are in place.
		This results in broader good business practice, encompassing operational procedures that encourage proper maintenance of their facility as a working environment.
		This includes regular site litter patrols to ensure that no materials are left lying around that could become a litter hazard.
3.	Manage litter in office and staff break areas.	Ferring Pharmaceutical continues to recycle all paper, plastics and ink cartridges arising in our small serviced facilities comprising offices and meeting rooms, together with the availability of proper waste bins.
		Staff are encouraged to make use of these waste and recycling facilities as part of our response to our APC signatory obligations which results in the minimisation of any litter in the office and staff break areas.

Ferring Pharmaceuticals regularly visits our logistics provider. We see, firsthand, the practices and procedures that are followed (in line with OH&S and broader good business practice) to ensure that there is no build-up of litter on their premises.

Office staff are encouraged to make use of the waste and recycling facilities as part of our response to our APC signatory obligations which results in the minimisation of any litter in the office and staff break areas.

Your Experiences

This section lets you share with us any achievements, good news stories and areas of difficulties in making progress against your plan and the Covenant goals and KPIs.

30. Key achievements or good news stories

With the announcement in the middle of 2015 that the current APC will be extended for another year to 30th June 2016 and since our existing Action plan has expired, we are developing a transitional plan which will enable us to continue to meet, and build on, our signatory obligations. This should place us in a strong position to develop the necessary plans and activities in response to the new Covenant when it comes into force in the second half of 2016.

Ferring Pharmaceuticals is a beneficiary of the Group's Corporate Social Responsibility (CSR) program being rolled out globally, committing the global operations of the Ferring Group to the four CSR 'pillars' of People, Business Ethics, Environment and Community. We can also contribute to the CSR program through our interaction with Head Office regarding our APC and SPG obligations.

Ferring Pharmaceuticals is proud of its continued support of a number of Australian consumer health organisations through corporate membership and project funding.

31.	31. Areas of difficulties in making progress against your plan, Covenant goals or KPIs				